Novo Nordisk is preparing to unveil data for a “next generation” weight-loss drug it believes could lead the field of GLP-1 treatments, as drugmakers seek to better the results of blockbuster treatments Wegovy and Mounjaro.
The company expects late-stage data for CagriSema, due to be published next month, to show that the drug cuts weight by 25 per cent in just over a year. That compares with up to 16 per cent from Novo Nordisk’s Wegovy, and up to 22.5 per cent from Eli Lilly’s rival Mounjaro when administered alongside lifestyle interventions such as improved diet, exercise and sleep.
“CagriSema is really important for us. It’s a next-generation product and it has the potential to be best in class,” chief executive Lars Fruergaard Jørgensen told the Financial Times at the release this month of the company’s third-quarter results, adding that he had not yet seen final data for the compound.